Osaka University

Kobe University

Keiichi Ozono

Takane Katayama

Toshiro Shirakawa

Yoshiko Hashii

Takanobu Otomo

Norio Sakai

A cancer vaccine that can be orally administered can be provided through the use of a transformedcapable of expressing and displaying a WT1 protein. The WT1 protein expressed and displayed by the transformedis a protein covering most of a WT1 protein unlike a WT1 peptide vaccine restricted to a certain HLA. A cancer vaccine using the transformedas an active ingredient is applicable to patients of various HLA types.

Oral cancer vaccine

The purpose of the present invention is to provide, in a simple and also inexpensive manner, a pharmaceutical composition which comprises a plurality of lysosomal enzymes and is effective in treating lysosomal storage disease caused by a deficiency in a plurality of lysosomal enzymes. Provided is a pharmaceutical composition for treating lysosomal storage disease, the composition comprising as an active ingredient a lysosomal enzyme group obtained from cells derived from a subject who does not suffer from lysosomal storage disease.

Pharmaceutical composition for treating lysosomal storage disease

Growing community of inventors

Osaka, Japan

Keiichi Ozono